Recombinant Human TRAIL/Apo2 Ligand (Carrier-Free)
| Cat No. | Size | Price | Quantity | |
|---|---|---|---|---|
| 21-9180-U010 | 10 µg | $80.00 | ||
| 21-9180-U050 | 50 µg | $195.00 | ||
| 21-9180-U100 | 100 µg | $300.00 | ||
| 21-9180-U500 | 500 µg | $900.00 |
Lead time: 2-3 business days
Technical Data Sheet
Request Custom/BulkDescription
TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic "death domain", which activates the cell's apoptotic machinery. The full length human TRAIL/Apo2L is a 281 amino acid protein, consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 243 amino acid extracellular domain.
TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic "death domain", which activates the cell's apoptotic machinery. The full length human TRAIL/Apo2L is a 281 amino acid protein, consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 243 amino acid extracellular domain.
Hide
Product Details
| Name | Recombinant Human TRAIL/Apo2 Ligand (Carrier-Free) |
|---|---|
| Cat. No. | 21-9180 |
| Alternative Names | TNFRelated Apoptosis-Inducing Ligand, TNF-αSF10, Apo2 Ligand, TL2 |
| Amino Acid Sequence | MRERGPQRVA AHITGTRGRS NTLSSPNSKN EKALGRKINS WESSRSGHSF LSNLHLRNGE LVIHEKGFYY IYSQTYFRFQ EEIKENTKND KQMVQYIYKY TSYPDPILLM KSARNSCWSK DAEYGLYSIY QGGIFELKEN DRIFVSVTNE HLIDMDHEAS FFGAFLVG |
| Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
| Bioactivity | Assay#1:Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells. The expected ED50 for this effect is 1.0-3.0 ng/ml. Assay#2:Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells). The expect |
| Endotoxin Level | Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg). |
| Molecular Mass | Recombinant Human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF-αhomologous portion of the extracellular domain of the full length TRAIL/Apo2L protein. |
| Protein Content | Content Verified by UV Spectroscopy and/or SDS-PAGE gel. |
| Purity (%) | 98 |
| Source | E. coli |
| Reactivity | Human |
| Research Areas | TNF-α Superfamily, Apoptosis, Cancer |
| Reconstitution | See Certificate of Analysis (COA) for lot specific reconstitution information. |
| Application | Bioassay |
Application Key:
FC = Flow Cytometry; FA = Functional Assays; ELISA = Enzyme-Linked Immunosorbent Assay; ICC = Immunocytochemistry; IF = Immunofluorescence Microscopy; IHC = Immunohistochemistry; IHC-F = Immunohistochemistry, Frozen Tissue; IHC-P = Immunohistochemistry, Paraffin-Embedded Tissue; IP = Immunoprecipitation; WB = Western Blot; EM = Electron Microscopy
*Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult the Materials and Methods section for additional details about the use of any product in these publications.